To Board of Directors Wockhardt Limited Mumbai

AUDIT REPORT on Financial Statements of Wockhardt Farmaceutica SA DE CV, Mexico for the year ended March 31, 2016

Wockhardt Farmaceutica SA DE CV is an indirect subsidiary company of Wockhardt Limited, India. Wockhardt Farmaceutica SA DE CV is incorporated in Mexico.

This report is furnished, at the request of the management of Wockhardt Limited, solely for the purpose of meeting with the requirements of consolidation of the attached financial statements of Wockhardt Farmaceutica SA DE CV with the financial statements of Wockhardt Limited, the ultimate Holding Company. The financial statements dealt with by this report comprise the Balance Sheet as at March 31, 2016 and Profit & Loss Account for the year ended on that date.

Accordingly, we have audited the aforesaid financial statements of Wockhardt Farmaceutica SA DE CV accompanying this report.

These financial statements are the responsibility of the management of Wockhardt Farmaceutica SA DE CV and Wockhardt Limited. And these have been prepared on the basis of accounts maintained by Wockhardt Farmaceutica SA DE CV at Mexico. As an additional presentation, these audited financial statements (in USD), have also been translated by the management in Indian Rupees (INR) at the exchange rate on the date of the balance sheet.

Our responsibility is to express an opinion on these financial statements based on our audit.

We have conducted our audit on the basis of accounting returns received from the office of Wockhardt Farmaceutica SA DE CV at Mexico (not visited by us) and information and explanations furnished and on the basis of such checks as were considered appropriate, and in the light of generally accepted accounting principles prevalent in India and in the light of materiality. We believe that our audit provides a reasonable basis for our opinion.

Based on our audit in the manner aforesaid and the fact that we have conducted our audit on the basis of accounting returns received from Wockhardt Farmaceutica SA DE CV at Mexico whose office has not been visited by us, and to the best of our information and according to the explanations given to us, we are of the opinion that the financial statements give a true and fair view:

- (a) in the case of the balance sheet, of the state of affairs of Wockhardt Farmaceutica SA DE CV as at March 31, 2016; and
- (b) in the case of the profit and loss account, of the profit for the year then ended.

For J.L. Thakkar & Co. Firm Regn No. 110898W Chartered Accountants

J.L. Thakkar – M.No.32318 Proprietor

Mumbai: April 27, 2016

WOCKHARDT FARMACEUTICA SA DE CV

BALANCE SHEET AS AT MARCH 31, 2016

	AS AT 31.03.2016 USD	AS AT 31.03.2016 INR @ 66.26
SOURCES OF FUNDS		
SHAREHOLDERS' FUNDS		
Share capital		
Equity share capital	2,886,220	191,240,937
Reserves and surplus	(8,246,935)	(546,441,913)
	(5,360,715)	(355,200,976)
APPLICATION OF FUNDS		
FIXED ASSETS		
Gross block	54,089	3,583,937
Accumulated depreciation	(18,706)	(1,239,460)
Net block	35,383	2,344,477
CURRENT ASSETS, LOANS AND ADVANCES		
Inventories	437,258	28,972,715
Sundry debtors	4,100,303	271,686,077
Cash and bank balances	30,825	2,042,465
Loans and advances	-	
CURRENT LIABILITIES AND PROVISIONS	4,568,386	302,701,257
Current Liabilities Current Liabilities	9,936,450	650 200 177
Provisions	9,936,430 28,034	658,389,177 1,857,533
FIGUISIONS	9,964,484	660,246,710
NET CURRENT ASSETS	(5,396,098)	(357,545,453)
	(5,360,715)	(355,200,976)

As per our report of even date

For J.L. Thakkar Co. Chartered Accountants For and on behalf of the Board
WOCKHARDT FARMACEUTICA SA DE CV

J.L. Thakkar Proprietor

Place: Mumbai Date: April 27, 2016 Director

WOCKHARDT FARMACEUTICA SA DE CV

PROFIT AND LOSS ACCOUNT FOR THE YEAR ENDED MARCH 31, 2016

	For the Year ended 31.03.2016 USD	For the Year ended 31.03.2016 INR @ 66.26	
INCOME			
Sales and services	1,417,304	93,910,563	
Other income	-	-	
	1,417,304	93,910,563	
EXPENDITURE			
Materials consumed and purchase of goods	1,226,268	81,252,518	
(Increase) / decrease in inventories	(25,946)	(1,719,182)	
Operating and other expenses	2,730,906	180,949,832	
Depreciation / Amortisation	6,202	410,945	
Financing cost	(190,933)	(12,651,221)	
	3,746,497	248,242,892	
NET PROFIT / (LOSS) BEFORE TAX FOR THE YEAR	(2,329,193)	(154,332,329)	
Provision for tax			
- Current tax	-	-	
- Deferred tax	-	-	
NET PROFIT / (LOSS) AFTER TAX FOR THE YEAR	(2,329,193)	(154,332,329)	
As per our report of even date			
For J.L. Thakkar Co.	For and on behalf of the Board		

J.L. Thakkar Proprietor

Place: Mumbai Date: April 27, 2016

Chartered Accountants

Director

WOCKHARDT FARMACEUTICA SA DE CV